Newbury Pharmaceuticals (NEWBRY) Q3 2025 earnings summary

Executive summary

• Net revenue for Q3 rose to SEK 6,686k, a 382% increase year-over-year, with EBITDA loss narrowing to SEK -5,691k from SEK -7,861k.

• Year-to-date net revenue reached SEK 25,658k, up 63% year-over-year, with EBITDA at SEK -10,423k versus SEK -14,742k.

• Nordic markets drove 88% of turnover year-to-date, up from 38% last year, while international sales lagged.

• Product launches and portfolio expansion in the Nordics are expected to drive future growth.

Financial highlights

• Q3 operating cash flow improved to SEK -5,787k from SEK -10,182k year-over-year.

• Cash position at period end was SEK 11,672k, down from SEK 15,431k last year.

• Equity at period end was SEK 53,520k, with equity per share at SEK 2.02.

• Gross proceeds of SEK 16m raised via directed share issue to support growth and strengthen capital structure.

Outlook and guidance

• Additional product launches in the Nordics planned for Q4, with full impact expected next year.

• Targeting positive EBITDA and long-term growth through portfolio expansion and new launches.

• Approximately 25 products expected to be launched by year-end.